There are many treatments for endometrial cancer, and the choice of treatment will depend on the extent (stage) of your disease along with other things. Jemperli is a treatment for endometrial cancer.

The U.S. Food and Drug Administration (FDA) has approved a new drug for certain adult patients with endometrial cancer. Jemperli (dostarlimab-gxly) — made by British pharmaceutical company GSK ...

GSK has built the case for first-line use of its PD-1 inhibitor Jemperli in endometrial cancer, with new survival data that could help it expand the label for the drug. The latest readout from the ...

Immunotherapy drugs approved to treat endometrial cancer are: Dostarlimab (Jemperli) Durvalumab (Imfinzi) Pembrolizumab (Keytruda) Your doctor may check your tumor cells for certain ...

On Thursday, the FDA expanded the endometrial cancer use for GSK’s Jemperli, used in combination with chemotherapy, to include patients with mismatch repair proficient (pMMR) or microsatellite ...

FDA approval for Jemperli plus chemotherapy was expanded to include all adult patients with primary advanced or recurrent endometrial cancer in August 2024. More on GSK GSK plc (GSK) 43rd Annual J ...

In 2023, the FDA approved Jemperli (dostarlimab) with chemotherapy for patients with advanced or recurrent endometrial cancer that is dMMR or microsatellite instability-high (cancer cells with many ...

GSK’sGSK-0.21%decrease; red down pointing triangle cancer drug Jemperli cleared an important ... of adult patients with primary or recurrent endometrial cancer who are candidates for systemic ...

Recently the FDA approved a new immunotherapy medication, Jemperli, which “dramatically changed the landscape for women with endometrial cancer,” Lewin says. It’s been almost four years ...

GSK (NYSE:GSK) has received expanded approval from the European Commission for its drug Jemperli, also known as dostarlimab, in the treatment of endometrial cancer. EU regulators have approved the ...